Pfizer announces additional phase 2/3 study results confirming robust efficacy of novel COVID-19 oral antiviral treatment candidate in reducing risk or hospitalization or death

Pfizer, Press Release, NCT05011513, Dec 2021

Outcome

Improvement

Relative Risk · 95% CI

Hospitalization

70%0.30 · 0.08–1.08

00.511.52+

← Paxlovid
reduces riskPaxlovid
increases risk →

Lower hospitalization with paxlovid

Not statistically significant · p = 0.051

.hsva .va--anim-stagger :is(.va__row,.plot__row,.va__verdict){opacity:1}.hsva .va--anim .plot__shade{opacity:var(--shade-opacity)}.hsva .va--anim-stagger .ci{transform:translateY(-50%)}.hsva .va--anim-stagger .pt{transform:none}.hsva .va--anim-settle .pt{left:calc(min(var(--pt), 2) / 2 * 100%)}.hsva .va--anim-settle .ci{left:calc(var(--lo) / 2 * 100%);width:calc((var(--hi) - var(--lo)) / 2 * 100%)}

EPIC-SR trial interim results, 428 patients treated with paxlovid (PF-07321332 + ritonavir) and 426 control patients, showing lower hospitalization with treatment. NCT05011513 (history).

Important missing comments or errors? Let us know.

risk of hospitalization, 70.1% lower, RR 0.30, p = 0.05, treatment 3 of 428 (0.7%), control 10 of 426 (2.3%), NNT 61.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Pfizer et al., 14 Dec 2021, Double Blind Randomized Controlled Trial, multiple countries, preprint, 1 author, study period 25 August, 2021 - 25 July, 2022, trial NCT05011513 (history).